Evidence map›Paper›PMID 34172718›Full record

ArticleBDJ open2021

Clinical efficacy of nanohydroxyapatite-containing toothpaste at relieving dentin hypersensitivity: an 8 weeks randomized control trial.

Bennett Tochukwu Amaechi, Kelly C Lemke, Shyamali Saha, Minh N Luong, Jonathan Gelfond

Open access · goldAbstract read
In one paragraph

Article in BDJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Nano-Hydroxyapatite (nHAp) in the Remineralization of Early Dental Caries: A Scoping Review.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bennett Tochukwu AmaechiDepartment of Comprehensive Dentistry, University of Texas Health San Antonio, San Antonio, TX, USA. amaechi@uthscsa.edu.ORCID http://orcid.org/0000-0002-5097-4466
Kelly C LemkeDepartment of Developmental Dentistry, University of Texas Health San Antonio, San Antonio, TX, USA.
Shyamali SahaDepartment of Comprehensive Dentistry, University of Texas Health San Antonio, San Antonio, TX, USA.
Minh N LuongDepartment of Comprehensive Dentistry, University of Texas Health San Antonio, San Antonio, TX, USA.
Jonathan GelfondDepartment of Epidemiology and Biostatistics, University of Texas Health San Antonio, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to investigate and compare the effectiveness of several toothpastes containing nanohydroxyapatite (nano-HAP) to relieve dentin hypersensitivity (DHS) with that of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (CSPS). MATERIALS AND

methodsIn this double-blind, randomized, parallel-group clinical trial, patients diagnosed with DHS and qualified to participate were randomized into four groups: toothpaste containing 10% nano-HAP (10%nano-HAP), 15% nano-HAP (15%nano-HAP), 10% nano-HAP supplemented with potassium nitrate (KNO

resultsWith either air or cold stimulus, VAS indicated a significant (P < 0.001) reduction from baseline DHS at each time point with all test toothpastes. Among the nano-HAP toothpastes, 15%nano-HAP and 10%nano-HAPKN were consistent in DHS reduction with both stimuli. With either stimuli, the CSPS did not significantly differ from 15%nano-HAP and 10%nano-HAPKN at any time point.

conclusionsToothpaste containing nano-HAP (10 or 15%) alone or supplemented with KNO

Identifiers

PMID34172718
PMCPMC8233401
OpenAlexW3173639011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.